Abstract:Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes that hydrolyse the intracellular second messengers cAMP and cGMP to their inactive forms 5'AMP and 5'GMP. Some members of the PDE family display specificity towards a single cyclic nucleotide messenger, and PDE4, PDE7, and PDE8 specifically hydrolyse cAMP. While the role of PDE4 and its use as a therapeutic target have been well studied, less is known about PDE7 and PDE8. This review aims to collate the present knowledge on human PDE7 and outline its potential use as a therapeutic target. Human PDE7 exists as two isoforms PDE7A and PDE7B that display different expression patterns but are predominantly found in the central nervous system, immune cells, and lymphoid tissue. As a result, PDE7 is thought to play a role in T cell activation and proliferation, inflammation, and regulate several physiological processes in the central nervous system, such as neurogenesis, synaptogenesis, and long-term memory formation. Increased expression and activity of PDE7 has been detected in several disease states, including neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's disease, autoimmune diseases such as multiple sclerosis and COPD, and several types of cancer. Early studies have shown that administration of PDE7 inhibitors may ameliorate the clinical state of these diseases. Targeting PDE7 may therefore provide a novel therapeutic strategy for targeting a broad range of disease and possibly provide a complementary alternative to inhibitors of other cAMP-selective PDEs, such as PDE4, which are severely limited by their side-effects.

Assays for Cyclic Nucleotide‐Specific Phosphodiesterases (PDEs) in the Central Nervous System (PDE1, PDE2, PDE4, and PDE10)

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

Microplate-based Method to Screen Inhibitors of Isozymes of Cyclic Nucleotide Phosphodiesterase Fused to SUMO

Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research

Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery

In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats

Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases

A novel cyclic GMP stimulated phosphodiesterase from rat brain.

Research progress of PDE4 in the central nervous system

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

Phosphodiesterase 2 and Its Isoform A as Therapeutic Targets in the Central Nervous System Disorders

Discovery of Novel PDE10 Inhibitors by a Robust Homogeneous Screening Assay.

PDE4D: A Multipurpose Pharmacological Target

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

A bioluminescent and homogeneous assay for monitoring GPCR-mediated cAMP modulation and PDE activity

The Measurement of Cyclic Nucleotide Phosphodiesterase 4 Activities Via the Quantification of Inorganic Phosphate with Malachite Green.

Pivotal role of phosphodiesterase 10A in the integration of dopamine signals in mice striatal D1 and D2 medium-sized spiny neurones

Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)

Phosphodiesterase 7 as a therapeutic target - Where are we now?

Determination of Ca2+/calmodulin-stimulated phosphodiesterase activity in intact cells.

The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors